CONNEQT scales US sales and expands market momentum

• CONNEQT Health’s FDA‑cleared Pulse device is driving strong US sales growth
• The company has placed a new 10,000-unit production order to meet growing consumer uptake
• Since its launch in January 2025, sales of the CONNEQT Pulse have increased by more than 50% quarter-on-quarter

Special Report: CONNEQT Health’s FDA‑cleared Pulse device is driving rapid US sales growth as adoption accelerates among consumers and clinicians seeking accessible, clinical-grade cardiovascular insights.

Since launching in January 2025, Pulse sales have jumped more than 50% quarter-on-quarter, generating US$325,000 in September-quarter revenue and improved advertising efficiency and return on spend.

The company is now operating at an annualised revenue run rate above US$3.5 million (A$5.4 million), with further acceleration expected in Q2 FY26 amid seasonal demand and fresh marketing initiatives.

To support the growth trajectory, CONNEQT (ASX:CQT) has placed a new 10,000-unit order with its manufacturing partner.

“In less than three quarters, we’ve scaled sales of the Pulse from zero at the start of the year to over A$5 million in annualised run‑rate revenue,” said CEO Craig Cooper.

“That kind of growth speaks volumes about both the demand and the market opportunity for our advanced arterial health monitors and validates our vision to make clinical‑grade cardiovascular insights accessible to everyone.”

Riding the Apple wave

The Pulse’s sales growth follows a high‑profile alignment with Apple’s newly announced hypertension detection feature for the Series 11 and Ultra 3 Apple Watches.

While Apple’s feature can flag potential hypertension, it still requires confirmation via a validated medical device – a gap that the CONNEQT Pulse is designed to fill.

The device is FDA-cleared and listed on the US Blood Pressure Validated Device List (VDL), offering structured cardiology reports, advanced arterial biomarkers, and seamless Apple Health integration.

“Apple has created an opportunity to catch hypertension before it causes damage,” said Cooper.

“Our Pulse monitor transforms those alerts into the validated clinical data that Watch users and doctors need to make informed treatment decisions. We’re not just measuring blood pressure, but instead completing Apple’s vision for proactive heart health.”

This article was developed in collaboration with CONNEQT, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.